Sam Brusco, Associate Editor02.04.22
Dexcom’s G6 continuous glucose monitoring (CGM) system is now eligible for Alberta Health public coverage for people with diabetes under 18 needing ongoing insulin use or insulin pump therapy. Alberta has joined five other jurisdictions providing public coverage for the technology under provincial health plans.
The Non-Insured Health Benefits Program also recently granted coverage to First Nations and Inuit children.
“We applaud the Alberta government for recognizing the value of real-time CGM and supporting access for its residents living with diabetes,” Laura Endres, senior VP and GM of Dexcom Canada told the press. “For youth in particular, diabetes management can make day-to-day life a challenge. Now, more young people living with diabetes will be able to learn and play with their peers with far less worry for their families about their glucose levels.”
Last year the Diabetes Canada Clinical Practice Guidelines updated glucose monitoring recommendations, stating real-time CGM technologies like Dexcom G6 is preferable for type 1 diabetes patients.1
Dexcom recently shared data at this year’s J.P Morgan Healthcare conference showing iis next-gen Dexcom G7 CGM’s sensor fell within +/- 20 percent of confirmed self-taken glucose levels about 93 percent of the time during periods of high, low, and normal blood sugar.
The Dexcom G7 CGM was submitted for U.S. Food and Drug Administration review in 2021’s fourth quarter, and the company aims to roll it out this year.
Dexcom reported preliminary revenue of about $2.4 billion last year in the J.P Morgan presentation as well, representing 27 percent growth over the prior year.
Reference
1 Cheng AYY, Feig DS, Ho J, et al. Blood glucose monitoring in adults and children with diabetes: update 2021. Canadian Journal of Diabetes. 2021;45(7):580-587.
The Non-Insured Health Benefits Program also recently granted coverage to First Nations and Inuit children.
“We applaud the Alberta government for recognizing the value of real-time CGM and supporting access for its residents living with diabetes,” Laura Endres, senior VP and GM of Dexcom Canada told the press. “For youth in particular, diabetes management can make day-to-day life a challenge. Now, more young people living with diabetes will be able to learn and play with their peers with far less worry for their families about their glucose levels.”
Last year the Diabetes Canada Clinical Practice Guidelines updated glucose monitoring recommendations, stating real-time CGM technologies like Dexcom G6 is preferable for type 1 diabetes patients.1
Dexcom recently shared data at this year’s J.P Morgan Healthcare conference showing iis next-gen Dexcom G7 CGM’s sensor fell within +/- 20 percent of confirmed self-taken glucose levels about 93 percent of the time during periods of high, low, and normal blood sugar.
The Dexcom G7 CGM was submitted for U.S. Food and Drug Administration review in 2021’s fourth quarter, and the company aims to roll it out this year.
Dexcom reported preliminary revenue of about $2.4 billion last year in the J.P Morgan presentation as well, representing 27 percent growth over the prior year.
Reference
1 Cheng AYY, Feig DS, Ho J, et al. Blood glucose monitoring in adults and children with diabetes: update 2021. Canadian Journal of Diabetes. 2021;45(7):580-587.